Incannex Healthcare (BST:IQI0) - Aktienkurs, Nachrichten und Analyse

IQI0 Aktienübersicht

A clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies.

Über das Unternehmen

IQI0 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Belohnungen

Risikoanalyse

Die Erträge sind in den letzten 5 Jahren um 43.7% pro Jahr zurückgegangen

Erzielt weniger als 1 Million USD an Einnahmen (A$1M)

Aktien sind hochgradig illiquide

Hat keine nennenswerte Marktkapitalisierung (€65M)

+ 2 mehr Risiken

Incannex Healthcare Inc. Wettbewerber

Apontis Pharma

XTRA:APPH

€69.5m

Redx Pharma

DB:0RX

€65.0m

SynBiotic

DUSE:SBX

€38.8m

Pierrel

DB:2FJ0

€92.8m

Preisentwicklung & Leistung

Summary of all time highs, changes and price drops for Incannex Healthcare
Historical stock prices
Current Share Price	US$1.43
52 Week High	US$1.78
52 Week Low	US$1.43
Beta	2.09
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-86.32%

Aktuelle Nachrichten und Updates

Recent updates

Aktionärsrenditen

	IQI0	DE Pharmaceuticals	DE Markt
7D	0%	-2.0%	-1.8%
1Y	n/a	-15.6%	1.7%

Rendite im Vergleich zur Industrie: Unzureichende Daten, um festzustellen, wie IQI0 im Vergleich zur Branche German Pharmaceuticals abschneidet.

Rendite vs. Markt: Unzureichende Daten, um festzustellen, wie IQI0 im Vergleich zum German Markt abgeschnitten hat.

Preisvolatilität

Is IQI0's price volatile compared to industry and market?
IQI0 volatility
IQI0 Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	5.1%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	10.4%
10% least volatile stocks in DE Market	2.6%

Stabiler Aktienkurs: IQI0 hatte in den letzten 3 Monaten keine nennenswerte Preisvolatilität.

Volatilität im Zeitverlauf: Unzureichende Daten, um die Volatilitätsveränderung von IQI0 im vergangenen Jahr zu bestimmen.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
2001	n/a	Joel Latham	www.incannex.com

Incannex Healthcare Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Incannex Healthcare im Vergleich zum Marktanteil des Unternehmens?
IQI0 grundlegende Statistiken
Marktanteil	€59.85m
Gewinn(TTM)	-€12.23m
Umsatz(TTM)	€620.84k

Over9,999x

Kurs-Umsatz-Verhältnis

-624.0x

Kurs-Gewinn-Verhältnis

Ist IQI0 zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
IQI0 Gewinn- und Verlustrechnung (TTM)
Einnahmen	AU$1.01m
Kosten der Einnahmen	AU$0
Bruttogewinn	AU$1.01m
Sonstige Ausgaben	AU$20.99m
Umsatz	-AU$19.98m

Zuletzt gemeldete Gewinne

Jun 30, 2023

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-0.013
Bruttomarge	100.00%
Nettogewinnspanne	-1,970.61%
Schulden/Eigenkapital-Verhältnis	0%

Wie hat sich IQI0 auf lange Sicht entwickelt?

Historische Performance und Vergleiche

IQI0 Aktienübersicht

Belohnungen

Risikoanalyse

Incannex Healthcare Inc. Wettbewerber

XTRA:APPH

€69.5m

DB:0RX

€65.0m

DUSE:SBX

€38.8m

DB:2FJ0

€92.8m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Incannex Healthcare Inc. Announces Patient Dosing Commencement in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea

Incannex Complete Successful Pre-Ind Meeting with the Fda for Cannquit-O for Treatment of Opioid Use Disorder

Incannex Healthcare Inc. Completes Successful Pre-IND Meeting with the FDA for CannQuit-N

Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis

Incannex Completes Dosing and Therapy in Phase 2 “Psigad” Clinical Trial Assessing Psilocybin-Assisted Psychotherapy for Generalized Anxiety Disorder

Incannex Healthcare Inc. Receives IRB Approval for the Reposa Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea

Recent updates

Incannex Healthcare Inc. Announces Patient Dosing Commencement in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea

Incannex Complete Successful Pre-Ind Meeting with the Fda for Cannquit-O for Treatment of Opioid Use Disorder

Incannex Healthcare Inc. Completes Successful Pre-IND Meeting with the FDA for CannQuit-N

Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis

Incannex Completes Dosing and Therapy in Phase 2 “Psigad” Clinical Trial Assessing Psilocybin-Assisted Psychotherapy for Generalized Anxiety Disorder

Incannex Healthcare Inc. Receives IRB Approval for the Reposa Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea

Incannex Healthcare Ltd. Receives Ethics Board Endorsement for Psychedelic Assisted Therapy At Its First Clinic Based in Melbourne, Australia

Incannex Healthcare Inc Update on Ihl-42X Drug Candidate in Phase 2/3 Clinical Trial in Obstructive Sleep Apnea

Incannex Healthcare Inc. SHS to Be Deleted from OTC Equity

Incannex Healthcare Limited Files Form 15

Psychennex Pty Ltd Commences Preparations of an Investigational New Drug Application to the U.S. Food and Drug Administration

Incannex Healthcare Limited Receives Approval from the US Food and Drug Administration to Conduct Its Investigational New Drug Opening Pivotal IHL-42X Phase 2/3 Clinical Trial in the United States

Incannex Healthcare Limited Completes Positive Pre-IND Meeting with US FDA on IHL-675A for Treatment of Rheumatoid Arthritis

Incannex Submits IND Application to the US FDA for IHL-42X for Obstructive Sleep Apnoea

Incannex Healthcare Limited Receives HREC Approval Ph 2 Clinical Trial for IHL675

Incannex Receives Ethics Approval for Bioequivalence/Bioavailability Clinical Trial for IHL-42X, the Company’S Proprietary Drug for Treatment of Obstructive Sleep Apnoea

Incannex Healthcare Limited Appoints Principal Investigators for IHL-42X Phase 2/3 Clinical Trial

Incannex Healthcare Limited Announces Independent Data Review Commences for PH 2 Trial Psilocybin

Incannex Healthcare Limited Expands Intellectual Property Position over IHL-42X

Incannex Healthcare Limited Announces Development Update for IHL-42X for Obstructive Sleep Apnoea

Incannex Healthcare Limited Announces Positive Preliminary Data from Ihl-675A Ph 1 Trial

Incannex Healthcare Limited Completes Positive Pre-IND Meeting with US FDA on IHL-216A for Treatment of Concussion and Traumatic Brain Injury

Incannex Healthcare Limited, Annual General Meeting, Nov 29, 2022

Incannex Healthcare Limited Appoints Robert B. Clark to the Board of Directors

Incannex Healthcare Limited (ASX:IHL) completed the acquisition of APIRx Pharmaceuticals USA, LLC from its shareholders.

Incannex Healthcare Limited Engages Curia to Scale-up Manufacture of cGMP IHL-216A

Incannex Healthcare Limited Receives Ethics Approval to Commence Phase 1 Clinical Trial of Multi-Use Anti-Inflammatory Drug IHL-675A

Incannex Healthcare Limited Announces Board Changes

Incannex Healthcare Limited Approves Election of George Anastassov as Director

Incannex Healthcare Limited Announces Positive Results from Phase 2 Clinical Trial Investigating the Effect of IHL-42X for Treatment of Obstructive Sleep Apnoea

Incannex Healthcare Limited Announces Positive Pre-IND Meeting with FDA for IHL-42X for Obstructive Sleep Apnoea

Incannex Healthcare Limited (ASX:IHL) completed the acquisition of APIRx Pharmaceuticals USA, LLC from its shareholders for $93.3 million on May 12, 2022.

Incannex Healthcare Limited Announces IHL-216A Was Observed to Have A Strong Neuroprotective Effect in A Widely Known Model of Sports Concussion

Aktionärsrenditen

Preisvolatilität

Über das Unternehmen

Incannex Healthcare Inc.'s Grundlagenzusammenfassung

Over9,999x

-624.0x

Erträge &amp; Einnahmen

Erträge & Einnahmen